DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on September 20, 2006; DOI: 10.1124/dmd.106.012054


0090-9556/06/3412-1958-1965$20.00
DMD 34:1958-1965, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.106.012054v1
34/12/1958    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kumar, S.
Right arrow Articles by Halpert, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kumar, S.
Right arrow Articles by Halpert, J. R.

Engineering of Cytochrome P450 3A4 for Enhanced Peroxide-Mediated Substrate Oxidation Using Directed Evolution and Site-Directed Mutagenesis

Santosh Kumar, Hong Liu, and James R. Halpert

Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, Texas (S.K., J.R.H.); and the Center for Drug Discovery and Design, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China (H.L.)

CYP3A4 has been subjected to random and site-directed mutagenesis to enhance peroxide-supported metabolism of several substrates. Initially, a high-throughput screening method using whole cell suspensions was developed for H2O2-supported oxidation of 7-benzyloxyquinoline. Random mutagenesis by error-prone polymerase chain reaction and activity screening yielded several CYP3A4 mutants with enhanced activity. L216W and F228I showed a 3-fold decrease in Km, HOOH and a 2.5-fold increase in kcat/Km, HOOH compared with CYP3A4. Subsequently, T309V and T309A were created based on the observation that T309V in CYP2D6 has enhanced cumene hydroperoxide (CuOOH)-supported activity. T309V and T309A showed a >6- and 5-fold higher kcat/Km, CuOOH than CYP3A4, respectively. Interestingly, L216W and F228I also exhibited, respectively, a >4- and a >3-fold higher kcat/Km, CuOOH than CYP3A4. Therefore, several multiple mutants were constructed from rationally designed and randomly isolated mutants; among them, F228I/T309A showed an 11-fold higher kcat/Km, CuOOH than CYP3A4. Addition of cytochrome b5, which is known to stimulate peroxide-supported activity, enhanced the kcat/Km, CuOOH of CYP3A4 by 4- to 7-fold. When the mutants were tested with other substrates, T309V and T433S showed enhanced kcat/Km, CuOOH with 7-benzyloxy-4-(trifluoromethyl)coumarin and testosterone, respectively, compared with CYP3A4. In addition, in the presence of cytochrome b5, T433S has the potential to produce milligram quantities of 6ß-hydroxytestosterone through peroxide-supported oxidation. In conclusion, a combination of random and site-directed mutagenesis approaches yielded CYP3A4 enzymes with enhanced peroxide-supported metabolism of several substrates.


Address correspondence to: Santosh Kumar, Department of Pharmacology and Toxicology, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555-1031. E-mail: sakumar{at}utmb.edu




This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
S. Kumar, H. Qiu, N. Oezguen, H. Herlyn, J. R. Halpert, and L. Wojnowski
Ligand Diversity of Human and Chimpanzee CYP3A4: Activation of Human CYP3A4 by Lithocholic Acid Results from Positive Selection
Drug Metab. Dispos., June 1, 2009; 37(6): 1328 - 1333.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
H. Sun, C. Moore, P. M. Dansette, S. Kumar, J. R. Halpert, and G. S. Yost
Dehydrogenation of the Indoline-Containing Drug 4-Chloro-N-(2-methyl-1-indolinyl)-3-sulfamoylbenzamide (Indapamide) by CYP3A4: Correlation with in Silico Predictions
Drug Metab. Dispos., March 1, 2009; 37(3): 672 - 684.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. Oezguen, S. Kumar, A. Hindupur, W. Braun, B. K. Muralidhara, and J. R. Halpert
Identification and Analysis of Conserved Sequence Motifs in Cytochrome P450 Family 2: FUNCTIONAL AND STRUCTURAL ROLE OF A MOTIF 187RFDYKD192 IN CYP2B ENZYMES
J. Biol. Chem., August 1, 2008; 283(31): 21808 - 21816.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
W. A. Johnston, W. Huang, J. J. De Voss, M. A. Hayes, and E. M.J. Gillam
A Shuffled CYP1A Library Shows Both Structural Integrity and Functional Diversity
Drug Metab. Dispos., December 1, 2007; 35(12): 2177 - 2185.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
S. Kumar, Y. Zhao, L. Sun, S. S. Negi, J. R. Halpert, and B. K. Muralidhara
Rational Engineering of Human Cytochrome P450 2B6 for Enhanced Expression and Stability: Importance of a Leu264->Phe Substitution
Mol. Pharmacol., November 1, 2007; 72(5): 1191 - 1199.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.